Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice

AIMS: Oligoprogression is poorly defined in current literature. Little is known about the natural history and significance of oligoprogression in patients with hormone-resistant prostate cancer on abiraterone or enzalutamide treatment [termed androgen receptor-targeted therapy (ARTT)]. The aim of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Priyanka H., Tunariu, Nina, Levine, Daniel S., de Bono, Johann S., Eeles, Rosalind A., Khoo, Vincent, Murray, Julia, Parker, Christopher C., Pathmanathan, Angela, Reid, Alison, van As, Nicholas, Tree, Alison C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152030/
https://www.ncbi.nlm.nih.gov/pubmed/35656509
http://dx.doi.org/10.3389/fonc.2022.862995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152030/
https://www.ncbi.nlm.nih.gov/pubmed/35656509
http://dx.doi.org/10.3389/fonc.2022.862995

Ejemplares similares